Dade Behring introduces in Europe assay for chronic alcohol abuse:
This article was originally published in Clinica
Executive Summary
Dade Behring has launched in Europe what is claimed to be the first fully-automated and direct immunoassay test for the early detection of chronic alcohol abuse. The N Latex CDT assay is designed for use on the company's BNII and BN ProSpec systems. Studies indicate that patients suffering from chronic alcohol abuse are characterised by elevated levels of carbohydrate-deficient transferrin (CDT), a serum protein found in the blood. The marker can also be used to differentiate the diagnosis of alcohol and non-alcohol induced liver disease, the Deerfield, Illinois firm said. The assay is not yet available in the US. Research estimates that around 20% of patients seen in clinical practice present underlying alcohol misuse.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.